Advertisement

Stimulants pp 99-165 | Cite as

Central Nervous System Stimulants: Historical Aspects and Clinical Effects

  • Burton Angrist
  • Abraham Sudilovsky
Part of the Handbook of Psychopharmacology book series (HBKPS, volume 11)

Abstract

The effects of central stimulants were identified early in the history of mankind; plants containing these substances are among the most ancient of known drugs. The use of ma huang (Ephedra vulgaris) in China, khat (Catha edulis) in Africa, and coca (Erythroxylon coca) in South America are examples of this early recognition. Thus, the Chinese herb ma huang, of acknowledged central stimulating activity, had been in use as a circulatory stimulant, diaphoretic, antipyretic, and antitussive agent (Chen and Schmidt, 1925) for some 5100 years before its main active ingredient, the sympathomimetic ephedrine, was introduced into clinical practice in the West for the treatment of asthma and similar conditions.

Keywords

Stereotyped Behavior Central Stimulant Central Nervous System Stimulant Coca Leave Amphetamine Abuse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alles, G. A., 1933, The comparative physiological actions of the DL β phenlisoproyplamines. I. Pressor effect and toxicity, J. Pharmacol. Exp. Therap. 47:339–354.Google Scholar
  2. Alles, G. A., Fairchild, M. D., and Jensen, M., 1961, Chemical pharmacology of Catha Edulis, J. Med. Pharmacol. Chem. 3(2):323–352.Google Scholar
  3. Anderson, E. W., and Scott, W. C. M., 1936, Cardiovascular effects of benzedrine, Lancet 2:1461–1462.Google Scholar
  4. Anggard, E., Gunne, L. M., Jonsson, L. E., and Nicklasson, F., 1970, Pharmacokinetic and clinical studies on amphetamine dependent subjects, Eur.J. Clin. Pharmacol. 3:3–11.Google Scholar
  5. Anggard, E., Jonsson, L. E., Hogmark, A. L., and Gunne, L. M., 1973, Amphetamine metabolism in amphetamine psychosis, Clin. Pharmacol. Therap. 14:870–880.Google Scholar
  6. Angrist, B., 1975, Contemporary Issues in Stimulant Research, Paper presented at Duke University, November 10–12.Google Scholar
  7. Angrist, B., and Gershon, S., 1969a, Amphetamine abuse in New York City—1966 to 1968, Sem. Psychiat. 1:195–207.Google Scholar
  8. Angrist, B., and Gershon, S., 1969b, Amphetamine induced schizophreniform psychosis in Schizophrenia: Current Concepts and Research (D. V. Sira Sankar, ed.), pp. 508–524, P. J. D. Publications Ltd., Hicksville, New York.Google Scholar
  9. Angrist, B., and Gershon, S., 1970, The phenomenology of experimentally induced amphetamine psychosis—Preliminary observations, Biol. Psychiat. 2:95–107.PubMedGoogle Scholar
  10. Angrist, B., and Gershon, S., 1972, Possible dose-response relationships in amphetamine psychosis, in Drug Abuse—Proceedings of the International Conference (C. J. D. Zarafonetis, ed.), pp. 263–269, Lea and Febriger, Philadelphia.Google Scholar
  11. Angrist, B., and Gershon, S., 1974, Dopamine and psychotic states: Preliminary remarks, in Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 211–219, Raven Press, New York.Google Scholar
  12. Angrist, B., Schweitzer, J., Friedhoff, A. J., Gershon, S., Hekiman, L. J., and Floyd, A., 1969, The chemical symptomatology of amphetamine psychosis and its relationship to amphetamine levels in urine, Int. Pharmacopsychiat. 2:125–139.Google Scholar
  13. Angrist, B., Shopsin, B., and Gershon, S., 1971, The comparative psychotomimetic effects of stereoisomers of amphetamine, Nature 234:152–153.PubMedGoogle Scholar
  14. Angrist, B., Shopsin, B., Gershon, S., and Wilk, S., 1972, Metabolites of monoamines in urine and cerebrospinal fluid after large dose amphetamine administration, Psychopharmacologia 26:1–9.PubMedGoogle Scholar
  15. Angrist, B., Sathananthan, G., and Gershon, S., 1973, Behavioral effects on L-dopa in schizophrenic patients, Psychopharmacologia 31:1–12.PubMedGoogle Scholar
  16. Angrist, B., Lee, H. K., and Gershon, S., 1974a, The antagonism of amphetamine-induced symptomatology by a neuroleptic, Am. J. Psychiat. 131:817–819.PubMedGoogle Scholar
  17. Angrist, B., Sathananthan, G., Wilk, S., and Gershon, S., 1974b, Amphetamine psychosis: Behavioral and biochemical aspects, J. Psychiat. Res. 11:13–23.PubMedGoogle Scholar
  18. Angrist, B., Wilk, S., and Gershon, S., 1974c, The effect or probenecid and large dose amphetamine administration on cerebrospinal fluid homovanillic acid, Biol. Psychiat. 8:113–114.PubMedGoogle Scholar
  19. Angrist, B., Thompson, H., Shopsin, B., and Gershon, S., 1975, Clinical studies with dopamine—receptor stimulants, Psychopharmacologia 44:273–280.PubMedGoogle Scholar
  20. Aschenbrandt, T., 1883, Die physiologische Wirkung and Bedeutung des Cocain insbesondere auf den menschlichen Organismus, klinische Beabachtungen wahrend der Herbs-twaftenubung, 1883 keim 11, Bayer A.C. 4 Div. 9 Reg. 2, Bat., Deutsche Med. Wochrenschr. 50:730–732.Google Scholar
  21. Ashkroft, G. W., Eccleston, D., and Waddell, J. L., 1965, Recognition of amphetamine addicts, Br. Med. J. 1:57.Google Scholar
  22. Axelrod, J., Kopin, J. J., and Mann, J. F., 1959, 3-Methoxy-4-hydroxyphenyl glycol sulfate, a new metabolite of epinephrine and norepinephrine, Biochem. Biophys. Acta (Amst.) 36:579.Google Scholar
  23. Ayd, F. J., Jr., 1964, Protracted administration of methylphenidate (Ritalin), Psychosomatics 5:180–187.PubMedGoogle Scholar
  24. Barger, G., and Dale, H. H., 1910, Chemical structure and sympathomimetic action of amines, J. Physiol. 41:19–59.PubMedGoogle Scholar
  25. Bartholomew, A. A., 1970, Amphetamine addiction, Med. J. Australia 1:1209–1214.PubMedGoogle Scholar
  26. Bartholomew, A. A., and Marley, E., 1959, Toxic response to 2-phenyl-3-methyl-tetrahydro-1,4-oxazine hydrochloride “Preludin” in humans, Psychopharmacologia 1:124–139.PubMedGoogle Scholar
  27. Beamish, P., and Kiloh, L. G., 1960, Psychoses due to amphetamine consumption, J. Ment. Sci. 106:337–343.PubMedGoogle Scholar
  28. Beck, L., Langford, W. S., Mackay, M., and Sum, G., 1975, Childhood chemotherapy and later drug abuse and growth curve: A follow-up study of 30 adolescents, Am. J. Psychiat. 132:436–438.PubMedGoogle Scholar
  29. Beckett, A. H., 1969, Discussion, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 525–528, Almqvist and Wiksell, Stockholm.Google Scholar
  30. Beckett, A. H., and Rowland, M., 1964, Rhythmic urinary excretion of amphetamine in man, Nature 204:1203–1204.PubMedGoogle Scholar
  31. Beckett, A. H., and Rowland, M., 1965, Urinary excretion kinetics of methylamphetamine in man, J. Pharm. Pharmacol. 17:109S–114S.Google Scholar
  32. Bejerot, N., 1968, An epidemic of phenmetrazine dependence, epidemiological and clinical aspects, in Adolescent Drug Dependence (C. W. M. Wilson, ed.), pp. 55–66, Pergamon Press, London.Google Scholar
  33. Bejerot, N., 1969, Intravenous drug abuse in the arrest population in Stockholm; frequency studies, in Abuse of Central Stimulants (F. Sjovist and M. Tottie, eds.), pp. 235–249, Almqvist and Witsell, Stockholm.Google Scholar
  34. Bell, D. S., 1965, A comparison of amphetamine psychosis and schizophrenia, Br. J. Psychiat. 3:701–706.Google Scholar
  35. Bell, D. S., 1967, Addiction to stimulants, Med. J. Australia 1:41–45.PubMedGoogle Scholar
  36. Bell, D. S., 1973, The experimental reproduction of amphetamine psychosis, Arch. Gen. Psychiat. 29:35–40.PubMedGoogle Scholar
  37. Bell, D. S., and Trethowan, W. H., 1961a, Amphetamine addiction, J. New. Ment. Dis. 133:489–496.Google Scholar
  38. Bell, C. S., and Trethowan, W. H., 1961b, Amphetamine addiction and disturbed sexuality, Arch. Gen. Psychiat. 4:74–78.Google Scholar
  39. Bentley, W. H., 1880a, Erythoxylon coca in the opium and alcohol habits, Ther. Gaz. (Detroit) 4:253–254.Google Scholar
  40. Bentley, W. H., 1880b, Erythroxylon coca, Ther. Gaz. (Detroit) 4:350–351.Google Scholar
  41. Berg, D. F., 1970, Illicit Use of Dangerous Drugs in the United States: A Compilation of Studies, Surveys, and Polls, Drug Sciences Division—Office of Science and Drug Abuse Prevention—Bureau of Narcotics and Dangerous Drugs, U.S. Dept. of Justice, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  42. Bernfeld, S., 1953, Freud’s studies on cocaine, in Cocaine Papers by Sigmund Freud (R. Byck, ed.), p. 343, The Stonehill Publ. Co., New York.Google Scholar
  43. Berry, J. N., 1966, Acute myeloblastic leukemia in a benzedrine addict, South. Med. J. 59:1169–1179.PubMedGoogle Scholar
  44. Bethell, M.F., 1957, Toxic psychosis caused by Preludin, Br. Med. J. 1:30–31.PubMedGoogle Scholar
  45. Bett, W. R., 1952, William Steward Halsted (1852–1922), cocaine pioneer and addict, Br. J. Addict. 49:53–59.Google Scholar
  46. Bett, W. R., 1946, Benzedrine sulfate in clinical medicine: A survey of the literature, Postgrad. Med. J. 22:205–218.PubMedGoogle Scholar
  47. Bloomberg, W., 1940, End results of use of large doses of amphetamine sulfate over prolonged periods, New Eng. J. Med. 222:946–948.Google Scholar
  48. Bonhoff, G., and Lewrenz, H., 1954, Über Wechamine (Pervitin and Benzedrin), Springer-Verlag, Berlin-Gottingen-Heidelberg.Google Scholar
  49. Borg, E., 1961, Methylphenidate addiction, Nord. Med. 65:211–213.Google Scholar
  50. Bradley, C., 1937, The behavior of children receiving benzedrine, Am. J. Psychiat. 94:577–585.Google Scholar
  51. Bradley, C., and Bowen, M., 1941, Amphetamine therapy of childrens’; behavior disorders, Am. J. Orthopsychiat. 11:92–103.Google Scholar
  52. Brill, H., and Hirose, T., 1969, The rise and fall of a methamphetamine epidemic: Japan 1945–55, Sem. Psychiat. 1:179–192.Google Scholar
  53. Briscoe, O. V., and Hinterberger, 1968, A survey of the usage of amphetamines in parts of the Sydney community, Med. J. Australia 1:480–485.PubMedGoogle Scholar
  54. Brown, C. T., 1949, Benzedrine habituation, Mil. Surgeon 104:365–370.Google Scholar
  55. Brown, D., Winsberg, B. G., Bialer, I., and Press, M., 1973, Imipramine therapy and seizures: Three children treated for hyperactive behavior disorders, Am. J. Psychiat. 130:210–212.PubMedGoogle Scholar
  56. Buhler, A., 1948, De coca bij de Indianen van Zuid-Amerika (the coca among the Indians of South America), Ciba Tschr., Basel No. 32, pp. 1066-1079.Google Scholar
  57. Bull, C. S., 1884, Hydrochlorate of cocaine as a local anesthetic in ophthalmic surgery, Med. Rec. (N.Y.) 26:577–578.Google Scholar
  58. Byck, R. (ed.), 1974, Cocaine Papers by Sigmund Freud, The Stonehill Publ. Co., New York.Google Scholar
  59. Caldwell, A. E., 1970, Origins of Psychopharmacology, from CPZ to LSD, p. 19, Charles C. Thomas Publisher, Springfield, Illinois.Google Scholar
  60. Caplan, J., 1963, Habituation to diethylpropion (Tenuate), Canad. Med. Assoc. J. 88:943–944.PubMedGoogle Scholar
  61. Carey, J. T., and Mandel, J., 1969, The bay area “speed scene,” J. Psychedel. Drugs 2:189–209.Google Scholar
  62. Carothers, J. C., 1945, Mira as cause of insanity, E. African Med. J. 22:4–6.Google Scholar
  63. Chen, K. K., and Schmidt, C. F., 1925, The action of ephedrine, the active principle of the Chinese drug Ma Huang, J. Pharmacol. Exp. Ther. 24:339–357.Google Scholar
  64. Chopra, R. N., and Chopra, G. S., 1931, Cocaine habit in India, Indian J. Med. Res. XVIII(3): 1013–1046.Google Scholar
  65. Citron, B. P., Halpern, M., McCarron, M., Lundverg, G. D., McCormick, R., Pincus, I. J., Tatter, D., and Haverback, B. S., 1970, Necrotizing angietus associated with drug abuse, New Eng. J. Med. 283:1003–1011.PubMedGoogle Scholar
  66. Clein, L. J., 1957, Toxic psychosis caused by Preludin, Brit. Med. J. 1:282.Google Scholar
  67. Clein, L. J., and Benady, D. R., 1962, Case of diethylpropion addiction, Br. Med. J. 2:456.PubMedGoogle Scholar
  68. Cockett, R., and Marks, V., 1969, Amphetamine taking among young offenders, Br. J. Psychiat. 115:1203–1204.Google Scholar
  69. Cole, J., 1969, The amphetamines in child psychiatry: A review, Sem. Psychiat. 1:174–178.Google Scholar
  70. Cole, J., and Tatetsu, S., Discussion, in Current Concepts of Amphetamine Abuse (E. Ellinwood, Jr and S. Cohen, eds.), DHEW Publication No. (HSM) 72-9085, p. 132, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  71. Committee on Alcoholism and Addiction and Council on Mental Health, 1966, Dependence on amphetamines and other stimulant drugs, J.A.M.A. 197:193–197.Google Scholar
  72. Connell, P. H., 1958, Amphetamine Psychosis, Maudsley Monographs Number Five, Oxford Univ. Press, London, New York, Toronto.Google Scholar
  73. Connell, P. H., 1962, The amphetamines—I, Medical World (London) 1962:18–20.Google Scholar
  74. Connell, P. H., 1966, Clinical manifestations and treatment of amphetamine type of dependence. J.A.M.A. 196:718–723.Google Scholar
  75. Connell, P. H., 1968, Clinical aspects of amphetamine dependence, in Adolescent Drug Dependence (C. W. M. Wilson, ed.), pp. 41–53, Pergamon Press, London.Google Scholar
  76. Connors, C. K., and Eisenberg, L., 1963, The effects of methylphenidate on symptomatology and learning in disturbed children, Am. J. Psychiat. 120:458–464.Google Scholar
  77. Connors, C. K., Eisenberg, L., and Barcai, A., 1967, Effect of dextroamphetamine on children, Arch. Gen. Psychiat. 17:478–485.Google Scholar
  78. Crittenden, A., and Ruby, M., 1974, Cocaine: the champagne of drugs, The New York Times Magazine, Sept., 1.Google Scholar
  79. Cytryn, L., Gilbert, A., and Eisenberg, L., 1960, The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children: A double-blind study of eighty outpatients, Am. J. Orthopsychiat. 30:113–127.Google Scholar
  80. Davies, I. J., 1937, Benzedrine: review of its toxic effects with report of severe case of anemia following its ued, Br. Med. J. 2:615–617.PubMedGoogle Scholar
  81. Delay, J., and Deniker, P., 1952, 38 cas de psychoses traites par la cure prolongee et continuee de 4568, Ann. Med. Psych. 110:364.Google Scholar
  82. Delay, J., Pichot, P., and Genert, R., 1947, Le choc amphetaminique, Ann. Med. Psych. 2:271–274.Google Scholar
  83. Demarle, L. G., 1862, Sur la Coca, Paris.Google Scholar
  84. Dominic, J. A., and Moore, K. E., 1969, Supersensitivity to the central stimulant action of adrenergic drugs following discontinuation of a chronic diet of alpha-methyltyrosine, Psychopharmacologia 15:96–101.PubMedGoogle Scholar
  85. Dowdeswell, G. F., 1876, Observations on the properties and action of the leaf of the Coca plant, Erythroxylon coca, Lancet 1:631–633, 665-667.Google Scholar
  86. Drassado, A., and Schmidt, M., 1954, Ritalin ein zentrales Stimulous mit neuartiger chemischer Konstitution, Med. Monatsschr. 8:306.Google Scholar
  87. Edeleano, L., 1887, Über einige Derivate der Phenzmethacrylsaure, Ber. Deutsch. Chem. Ges. 20:616–622.Google Scholar
  88. Editorial, 1880, Erythroxylon coca as an antidote to the opium habit, Ther. Gaz. (Detroit), pp. 19-26, June 15.Google Scholar
  89. Editorial, 1937, Benzedrine sulfate “Pep Pills,” 1937, J.A.M.A. 108:1973-1974.Google Scholar
  90. Eisenberg, L., 1964, Role of drugs in treating disturbed children, U.S. Dept. Health Ed. Welfare 11:167–173.Google Scholar
  91. Eisenberg, L., Lachman, R., Milling, P. A., Lockner, A., Mizelle, J. D., and Connors, K., 1963, A psychopharmacologic experiment in a training school for delinquent boys, Am. J. Orthopsychiat. 33:431–447.Google Scholar
  92. Ellinwood, E. H., Jr., 1967, Amphetamine psychosis: I, Description of the individuals and process, J. Nerv. Ment. Dis. 144:273–283.Google Scholar
  93. Ellinwood, E. H., Jr., 1968, Amphetamine Psychosis: II, Theoretical implications, J. Neuropsychiat. 4:45–54.Google Scholar
  94. Ellinwood, E. H., Jr., 1971, Assault and homicide associated with amphetamine abuse, Am. J. Psychiat. 127:1170–1175.PubMedGoogle Scholar
  95. Ellinwood, E. H., Jr., 1972, Amphetamine psychosis: Individuals’ settings and sequences, in Current Concepts of Amphetamine Abuse (E. H. Ellinwood and S. Cohen, eds.), pp. 143–157, DHEW, Publ. No. HSM 72-9085, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  96. Ellinwood, E. H., Jr., and Escalante, O. D., 1970, Behavior and histopathological findings during chronic methedrine intoxication, Biol. Psychiat. 2:27–39.PubMedGoogle Scholar
  97. Ellinwood, E. H., Jr., and Sudilovsky, A., 1973, Chronic amphetamine intoxication: Behavioral model of psychoses, in Psychopathology and Psychopharmacology (J. O. Cole, A. M. Freedman, and A. J. Friedhoff, eds.), pp. 51–70, The Johns Hopkins Univ. Press, Baltimore.Google Scholar
  98. Ellinwood, E. H., Jr., Sudilovsky, A., and Nelson, L., 1972, Behavioral analysis of chronic amphetamine intoxication, Biol. Psychiat. 4:215–229.PubMedGoogle Scholar
  99. Ellinwood, E. H., Jr., Sudilovsky, A., and Nelson, L., 1973, Evolving behavior in the clinical and experimental amphetamine (model) psychosis, Am. J. Psychiat. 130:1088–1093.PubMedGoogle Scholar
  100. Emde, H., 1929, Über Diastereomerie, I. Konfiguration des Ephedrins, Helvet. Chim. Acta 12:265–376.Google Scholar
  101. Erlenmeyer, A., 1885, Über die Wirkung des Cocain bei der Morphiumentziehung, Centralbl. Nervenheilkunde VIII:289–299.Google Scholar
  102. Escalante, O. D., and Ellinwood, E. H., Jr., 1972, Effects of chronic amphetamine intoxication on adrenergic and cholinergic structures in the central nervous system: Histochemical observations in cats and monkeys, in Current Concepts of Amphetamine Abuse (E. H. Ellinwood, Jr., and S. Cohen, eds.), pp. 97–106, DHEW Pub. No. HSM 72-9085, NIMH, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  103. Espelin, D. E., and Done, H. K., 1968, Amphetamine poisoning effectiveness of chlorpromazine, New Eng. J. Med. 278:1361–1365.PubMedGoogle Scholar
  104. Evans, J., 1959, Psychosis and addiction to phenmetrazine (Preludin), Lancet, 2:152–155.PubMedGoogle Scholar
  105. Everett, G. M., 1973, Genetic factors in the control of brain levels of biogenic amines and brain excitability, in Frontiers in Catecholamine Research, (E. Usdin and S. H. Snyder, eds.), pp. 657–659, Pergamon Press, London.Google Scholar
  106. Fawcett, J., and Siomopoulos, V., 1971, Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression, Arch. Gen. Psychiat. 25:247–255.Google Scholar
  107. Freud, S., 1884, Über Coca, Centralbl. Ges. Ther. 2:289–314.Google Scholar
  108. Freud, S., 1887, Bemerkungen über Cocainancht und Cocainfurcht mit Beziehung auf einem Vortrag W. A. Hammond’s, Wien Med. Wschr. 28:929–932.Google Scholar
  109. Gaedcke, F., 1855, Arch. Pharm. 87, Paris.Google Scholar
  110. Gale, A. S., 1959, The clinical use of methylphenidate for central stimulation in oversedated patients, Anesth. Analg. Curr. Res. 38:406–412.Google Scholar
  111. Gallup Organization, 1969, Newsweek, December 29, 1969:42-45.Google Scholar
  112. Garattini, S., Jori, A., Samanin, R., 1976, Interactions of various drugs with amphetamine, Ann. N.Y. Acad. Sci. 281:409–425.PubMedGoogle Scholar
  113. Garcilaso de la Vega, 1871, The first part of the royal commentaries of the Incas, 1609, Vol. II, pp. 371–375, Hakluyt Society, London.Google Scholar
  114. Gay, G. R., Inaba, D. S., Sheppard, C. W., and Newmeyer, J. A., 1975, Cocaine: History, epidemiology, human pharmacology, and treatment. A perspective on a new debut for an old girl, Clin. Toxicol. 8(2): 149–175.PubMedGoogle Scholar
  115. Gericke, O. L., 1945, Suicide by ingestion of amphetamine sulfate, J.A.M.A. 128:1098–1099.Google Scholar
  116. Glatt, M. M., 1957, Toxic psychosis caused by Preludin, Br. Med. J. 1:460–461.Google Scholar
  117. Goldsmith, W. N., 1939, Benzedrine eruption, Proc. Roy. Soc. Med. 32:269.PubMedGoogle Scholar
  118. Goodman, S. J., and Becker, D. P., 1970, Intracranial hemorrhage associated with amphetamine abuse, J.A.M.A. 212:480.PubMedGoogle Scholar
  119. Graubner, W., and Bienert, H. R., 1968, Epidemic misuse of phenmetrazine and some data about a combination with a laxative, in Adolescent Drug Dependence (C. W. M. Wilson, ed.), pp. 67–71, Pergamon Press, London.Google Scholar
  120. Griffith, J., 1966, A study of illicit amphetamine drug traffic in Oklahoma City, Am. J. Psychiat. 123:560–569.PubMedGoogle Scholar
  121. Griffith, J., 1970, Discussion, in Psychotomimetic Drugs (D. Efron, ed.), p. 297, Raven Press, New York.Google Scholar
  122. Griffith, J., Oates, J. A., and Cavanaugh, J. H., 1968, Paranoid episodes induced by drug, J.A.M.A. 205:39.Google Scholar
  123. Griffith, J., Cavanaugh, J. H., and Oates, J., 1970, Psychosis induced by the administration of d-Amphetamine to human volunteers, in Psychotomimetic Drugs (D. Efron, ed.), pp. 287–294, Raven Press, New York.Google Scholar
  124. Griffith, J., Davis, J., and Oates, J., 1971, Amphetamines: Addiction to a non-addicting drug, Pharmakopsychiatrie Neuropsychopharmacologie 4:58–64.Google Scholar
  125. Grinspoon, L., and Hedblom, P., 1975, The Speed Culture, Harvard Univ. Press, Cambridge, Massachusetts, and London, England.Google Scholar
  126. Guerra, F., 1974, Sex and drugs in the 16th century, Br. J. Addict. 69:269–290.Google Scholar
  127. Guile, I., 1963, Intravenous methylphenidate—a pilot study, Med. J. Australia 2:93–97.Google Scholar
  128. Gullat, R., 1957, Acute methamphetamine poisoning in a child, Southern Med. J. 50:1068.Google Scholar
  129. Gunne, L. M., Anggard, E., and Jonsson, L. E., 1972, Clinical trials with amphetamine-blocking drugs, Psychiat. Neurol. Neurchir. (Amst.) 75:225–226.Google Scholar
  130. Gutierrez-Noriega, 1944, Datos historicos sobre la habituacion a la coca en el Peru, Rev. Med. Exp. 3:341.Google Scholar
  131. Guttmann, E., and Sargeant, W., 1937, Observations on benzedrine, Br. Med. J. 1937:1013–1015.Google Scholar
  132. Hall, R. J., 1884, Hydrochlorate of cocaine, N. Y. Med. J. 40:643–644.Google Scholar
  133. Hammond, W. A., 1886, Remarks on cocaine and the so-called cocaine habit, J. Nerv. Ment. Dis. 13:754–759.Google Scholar
  134. Hartert, D., and Browne-Mayers, A., 1958, The use of methylphenidate (Ritalin) hydrochloride in alcoholism, J.A.M.A. 166:1982–1985.Google Scholar
  135. Hauschild, F., 1938, Zur Pharmakologie des 1-phenyl-2-methyl-amino-propans (Pervitin), Arch. Exper. Path. U. Pharmacol. 191:465–481.Google Scholar
  136. Heisch, R. B., 1945, Case of poisoning by Catha edulis, E. African Med. J. 22:7–9.Google Scholar
  137. Hekimian, L. J., and Gershon, S., 1968, Characteristics of drug abusers admitted to a psychiatric hospital, J.A.M.A. 205:125–130.PubMedGoogle Scholar
  138. Hemmi, T., 1969, How we handled the problem of drug abuse in Japan, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 147–153, Almqvist and Wiksell, Stockholm.Google Scholar
  139. Herman, M., and Nagler, S. H., 1954, Psychoses due to amphetamine, J. Nerv. Ment. Dis. 120:268–272.PubMedGoogle Scholar
  140. Herridge, C. F., and a’Brook, M. F., 1968, Ephedrine psychosis, Br. Med. J. 2:160.PubMedGoogle Scholar
  141. Hesse, E., 1946, Narcotics and Drug Addiction, Philosophical Library, New York.Google Scholar
  142. Hopkin, B., and Jones, C. M., 1956, Dextroamphetamine poisoning, Br. Med. J. 1:1044.Google Scholar
  143. Horowitz, M., 1974, Editor’s Preface, in History of Coca, “The Divine Plant” of the Incas by W. G. Mortimer, Fitz Hugh Ludlow Memorial Library Edition, San Francisco.Google Scholar
  144. Inghe, G., 1969, The present state of abuse and addiction to stimulant drugs in Sweden, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 187–214, Almqvist and Wiksell, Stockholm.Google Scholar
  145. Jacobson, A., 1958, The use of Ritalin in psychotherapy of depressions of the aged, Psychiat. Quart. 32:474–483.PubMedGoogle Scholar
  146. Janowsky, D., 1975, Discussion at Annual Meeting, Psychiatric Research Association, New York, November 1, 1975.Google Scholar
  147. Janowsky, D. S., and Davis, J. B., 1974, Dopamine psychomotor stimulants and schizophrenia: Effects of methylphenidate and the sterioisomers of amphetamine in schizophrenics, in Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 317–323, Raven Press, New York.Google Scholar
  148. Janowsky, D. S., and Davis, J. B., 1976, Methylphenidate, dextroamphetamine levamphetamine effects on schizophrenic symptoms, Arch. Gen. Psychiat. 33:304–308.PubMedGoogle Scholar
  149. Janowsky, D. S., El-Yousef, M. K., Davis, M. M., and Sekerke, H. S., 1973, Provocation of schizophrenic symptoms by intravenous administration of methylphenidate, Arch. Gen. Psychiat. 28:185–191.PubMedGoogle Scholar
  150. Johanson, C. E., and Schuster, C. R., 1975, Presented at annual meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 18, 1975.Google Scholar
  151. Johnson, J., and Milner, G., 1966, Amphetamine intoxication and dependence in admissions to a psychiatric unit, Br. J. Psychiat. 112:617–619.Google Scholar
  152. Jones, E., 1953, The Life and Works of Sigmund Freud, Vol. I (1856–1900), p. 91, Basic Books, New York.Google Scholar
  153. Jones, H. E., 1962, A trial of diethylpropion in the treatment of childhood obesity, Practitioner 188:229–231.PubMedGoogle Scholar
  154. Jonsson, C. O., 1969, Behavioral studies of diethylpropion in man, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 71–80, Almqvist and Wiksell, Stockholm.Google Scholar
  155. Jonsson, L. E., 1972, Pharmacological blockade of amphetamine effects in amphetamine dependent subjects, Eur. J. Clin. Pharmacol. 4:206–211.Google Scholar
  156. Jonsson, L. E., Gunne, L. M., and Anggard, E., 1969, Effects of alphamethyltyrosine in amphetamine dependent subjects, Pharmacol. Clin. 2:27–29.Google Scholar
  157. Jonsson, L. E., Anggard, E., and Gunne, L. M., 1971a, Blockade of intravenous amphetamine euphoria in man, Clin. Pharmacol. Therap. 12:889–896.Google Scholar
  158. Jonsson, L. E., Lewander, T., and Gunne, L. M., 1971b, Amphetamine psychoses: urinary excretion of catecholamines and concentrations of homovanillic acid (HVA) and 5-hydroxy-indoleacatic acid (5-HIAA) in the cerebrospinal fluid, Res. Comm. Chem. Path. Pharmacol. 2:335–369.Google Scholar
  159. Jorgensen, F., and Kodahl, T., 1961, On the abuse of Ritalin, Ugeskr Laeger 123:1275–1279.PubMedGoogle Scholar
  160. Jori, A., and Bernardi, D., 1972, Further studies on the increase of striatal homovanillic acid induced by amphetamine and fenfluramine. Eur. J. Pharmacol. 19:276–280.PubMedGoogle Scholar
  161. Kalant, O. J., 1973, The Amphetamines: Toxicity and Addiction, 2nd Ed., Brookside Monographs of the Addiction Research Foundation #5, Charles C Thomas, Springfield, Illinois, and University of Toronto Press, Toronto, Canada.Google Scholar
  162. Kalus, F., 1950, On psychotic symptoms in chronic abuse of Pervitin, F. Psychiat. Neurol. Medizin. Psychol. 2:109–116.Google Scholar
  163. Kane, F. J., and Florenzano, R., 1971, Psychosis accompanying the use of bronchodilator compound, J.A.M.A. 215:2116.PubMedGoogle Scholar
  164. Kasirsky, G., Zaidi, I. H., and Tansy, M. F., 1972, LD50 and pathologic effects of acute and chronic administration of methamphetamine HCl in rabbits, Res. Commun. Chem. Pathol. Pharmacol. 3:215–231.PubMedGoogle Scholar
  165. Kauvar, S. S., Henschel, E. J., and Ravin, A., 1943, Toxic eruption due to amphetamine sulfate and its analogue dextroamphetamine sulfate, J.A.M.A. 122:1073–1074.Google Scholar
  166. Kiloh, L. G., and Brandon, S., 1962, Habituation and addiction to amphetamines, Br. Med. J. 11:40–43.Google Scholar
  167. Klawans, H. L., 1973, The pharmacology of tardive dyskinesias, Am. J. Psychiat. 130:82–86.PubMedGoogle Scholar
  168. Klawans, H. L., and Margolin, D. I., 1975, Amphetamine induced dopaminergic hypersensitivity in guinea pigs, Arch. Gen. Psychiat. 32:723–732.Google Scholar
  169. Klein, D. F., and Davis, J. M., 1969, Diagnosis and Drug Treatment of Psychiatric Disorders, p. 303, Williams and Wilkins, Baltimore.Google Scholar
  170. Knapp, P. H., 1952, Amphetamines and addiction, J. Nerv. Ment. Dis. 115:406–432.PubMedGoogle Scholar
  171. Koller, C., 1884, Über die Vertvendung des Cocain zur Anasthesiong am Ange, Wiener Med. Woch. 1307.Google Scholar
  172. Kramer, J. C., 1969, Introduction to amphetamine abuse, J. Psychodel. Drugs, 1-16.Google Scholar
  173. Kramer, J. C., Fischman, V. S., and Littlefield, D. C. 1967, Amphetamine abuse: Pattern and effects of high doses taken intravenously, J.A.M.A. 201:305–309.PubMedGoogle Scholar
  174. Kramer, J. C., Ellinwood, E.H., and Angrist, B., 1972, Discussion, in Current Concepts of Amphetamine Abuse (E. H. Ellinwood, Jr., and S. Cohen, eds.), DHEW Publ. No. HSM 72-9085, pp. 131–132, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  175. Kuenssberg, E. V., 1962, Diethylpropion, Br. Med. J. 2:729–730.Google Scholar
  176. Landeman, M., Preisig, R., and Perlman, M., 1958, A practical mood stimulant, J. Med. Soc. New Jersey 55:55–58.Google Scholar
  177. Laurent, J. M., 1962, Toxique et toxicomanie peu connus, “le cath,” Ann. Medico-Psychol. 120:649–657.Google Scholar
  178. Leake, C. D., 1958, The Amphetamines, Their Actions and Uses, p. 4, Charles C Thomas, Springfield, Illinois.Google Scholar
  179. Lemberger, L., Witt, E. L, Davis, J. M., and Kapin, I. J., 1970, The effects of haloperidol and chlorpromazine on amphetamine metabolism and amphetamine stereotype behavior in the rat, J. Pharmacol. Exp. Therap. 174:428–433.Google Scholar
  180. Lesses, M. F., and Myerson, A., 1938, Correspondence, benzedrine, sulfate, J.A.M.A. 110:1507–1508.Google Scholar
  181. Lewander, T., 1969, Discussion, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 350–352, Almqvist and Wiksell, Stockholm.Google Scholar
  182. Lewander, T., 1972, Experimental and clinical studies on amphetamine dependence, in Biochemical and Pharmacological Aspects of Dependence and Reports on Marijuana Research (H. M. Van Praag, ed.), pp. 69–84, De Erven F. Bohn N.V., Haarlem, Netherlands.Google Scholar
  183. Lewander, T., 1974, Effect of chronic treatment with central stimulants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits, in Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 221–239, Raven Press, New York.Google Scholar
  184. Lewin, L., 1924, Der Kokainismus in Phantastica die Betaubenden und erregenden Geunssmittel für Artze und Nichtartze, Georg Stilke, Berlin.Google Scholar
  185. Lewis, A., 1968, Historical perspective, Br. J. Addict. 63:241–245.Google Scholar
  186. Lucas, A. R., and Weiss, M., 1971, Methylphenidate hallucinosis, J.A.M.A. 217:1079–1081.PubMedGoogle Scholar
  187. MgConnell, W. B., 1963, Amphetamine substances in mental illnesses in Northern Ireland, Br. J. Psychiat. 109:218–224.Google Scholar
  188. McCormick, T. C., Jr., 1962, Toxic reactions to the amphetamines, Dis. Nerv. Syst. 23:219–224.Google Scholar
  189. McCormick, T. C., Jr., and McNeil, T. W., 1962, Acute psychosis and Ritalin abuse, Texas State J. Med. 59:99–100.Google Scholar
  190. McNeil, D., 1967, An amphetamine apple in psychedelic eden, The Village Voice, February 2, 1967.Google Scholar
  191. Malmquist, J., Trell, E., Torp, A., and Lindstrom, C., 1970, A case of drug-induced (?) pulmonary hypotension, Acta Med. Scand. 188:265–272.PubMedGoogle Scholar
  192. Mantegazza, P., 1859, Sulle Virtu Igieniche e Medicinale della Coca, Memoria onorata del Premio dell’Acqua nel concorso di 1858, estratto dagli Annali Universali di Medicina, Milan.Google Scholar
  193. Margolis, M. T., and Newton, T. H., 1971, Methamphetamine (“speed”) arthritis, Neuroradiology 2:179–182.PubMedGoogle Scholar
  194. Mariani, A., 1896, Coca and Its Therapeutic Applications, J. N. Jaros, New York.Google Scholar
  195. Markham, C. C. B., 1862, Travels in Peru and India, pp. 152, Hakluyt Soc. Pub., London.Google Scholar
  196. Markham, C. C. B., 1880, Peruvian Bark; A Popular Account of the Introduction of Cinchona Cultivation into British India, p. 53, Hakluyt Soc. Pub., London.Google Scholar
  197. Martin, W. R., Sloan, J. W., Sapira, J. D., and Jasinski, D. R., 1971, Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man, Clin. Pharmacol. Therap. 12:245–258.Google Scholar
  198. Masaki, T., 1956, The amphetamine problem in Japan, World Health Organ. Tech. Rep. Serv. 102:14–21.Google Scholar
  199. Mathysse, S., 1974, Dopamine and the pharmacology of schizophrenia: The state of the evidence, J. Psychiat. Res. 11:107–113.Google Scholar
  200. Mattson, R. H., and Calverley, J. R., 1968, Dextroamphetamine sulfate-induced dyskinesias, J.A.M. A. 204:400–402.PubMedGoogle Scholar
  201. Meier, R., Gross, F., and Tripod, J., 1954, Ritalin, eine neuartige synthetische Verbindung mit spezifischer zentralerregender Wirkungskomponente, Klin. Wochenschr. 32:445–450.PubMedGoogle Scholar
  202. Meyerson, A., 1936, Effect of benzedrine sulfate on mood and fatigue in normal and neurotic persons, Arch. Neurol. Psychiat. 36:916–922.Google Scholar
  203. Meyler, L., 1960, Side Effects of Drugs, The Excerpta Medica Foundation, Amsterdam, p. 2.Google Scholar
  204. Mira, E., 1942, Am. J. Psychiat. 99:459–460.Google Scholar
  205. Mitchell, H. S., and Denton, R. L., 1950, Overdosage with dexedrine, Canad. Med. Assoc. J. 62:594–595.PubMedGoogle Scholar
  206. Moll, A. A., 1944, Aesculapius in Latin America, pp. 231, W. B. Saunders Co., Philadelphia.Google Scholar
  207. Monardes, N. B., 1577, Joyfull Newes out of the Newe Founde Worlde (translated by John Frampton, London, reported by S. Gaselee), Vol. 2, pp. 31–32, Knopf, New York.Google Scholar
  208. Monroe, R. R., and Drell, H. Z., 1947, Oral use of stimulants obtained from inhalers, J.AM.A. 135:909–915.Google Scholar
  209. Moreno y Maiz, T., 1868, Recherches chimiques et physiologiques sur l’Erythroxylon coca du Perou, et la cocaine, Thesis Univ. of Paris, Paris.Google Scholar
  210. Mortimer, W. G., 1901, History of Coca, “the Divine Plant” of the Incas, J. H. Vail, New York.Google Scholar
  211. Musto, D. F., 1968, A study in cocaine: Sherlock Holmes and Sigmund Freud, J.AM.A. 204:125–130.Google Scholar
  212. Myerson, Loman, and Dameshek, 1937, cited in Simpson (1937).Google Scholar
  213. Nathensohn, A. L., 1956, Clinical evaluation of Ritalin, Dis. Nerv. Syst. 17:1–4.Google Scholar
  214. Niemann, A., 1860, Über eine neue organische Base in den Cocablattern, Vierteljahresschrift für Praktische Pharmacie, Gottingen.Google Scholar
  215. Noreik, K., 1960, Methylphenidate addiction, T. Norsk Lageforen 80:442.Google Scholar
  216. Obersteiner, H., 1886, Uber Intoxication Psychosen, Wien. Med. Presse XXIV.Google Scholar
  217. O’Flannagan, P. M., and Taylor, R. B., 1950, A case of recurrent psychosis associated with amphetamine addiction, J. Ment. Sci. 96:1033–1036.Google Scholar
  218. Ogata, A., 1919, Desoxyephedrine—A contribution to the structure of ephedrine, J. Pharm. Soc. Japan 451:751–764.Google Scholar
  219. Oswald, I., and Thacore, V. R., 1963, Amphetamine and phenmetrazine addiction: Physiologic abnormalities in the abstinence syndrome, Br. Med. J. 2:427–434.PubMedGoogle Scholar
  220. Panse, F., 1964, Psychiatrische Krankheitsbilder in Sucht und Missbrauch (F. Laubenthal, ed.), pp. 169–202, Georg Thieme Verlag, Stuttgart.Google Scholar
  221. Parkes, J. D., Tarsy, D., Marsden, C. D., Bovill, K. T., Phipps, J. A., Rose, P., and Asselman, P., 1975, Amphetamine in the treatment of Parkinson’s disease, J. Neurol. Neurosurg. Psychiat. 38:232–237.PubMedGoogle Scholar
  222. Paris, R. R., and Moyse-Mignon, H., 1957, Characteristics of kat or Abyssinian tea (Catha edulis) listed as a poisonous substance, Ann. Pharm. France 15:89–98Google Scholar
  223. Paris, R. R., and Moyse-Mignon, H., 1958, U.N. Bull. Narcotics 10:29.Google Scholar
  224. Penick, S. B., 1969, Amphetamines on obesity, Sem. Psychiat. 1:144–162.Google Scholar
  225. Perel, J. M., Black, N., Wharton, R. N., and Malitz, J., 1969, Inhibition of imipramine metabolism by methylphenidate, Fed. Proc. 28:418.Google Scholar
  226. Perman, E. S., 1970, Speed in Sweden, New Eng. J. Med. 283:760–761.PubMedGoogle Scholar
  227. Peters, U. H., 1961, On the problem of methyphenidole addiction, Arch.Toxik. 19:199–204.PubMedGoogle Scholar
  228. Pharoh, N., 1964, “Het gets out of it,” New Society 3:8.Google Scholar
  229. Pickens, R., and Harris, W. C., 1968, Self-administration of d-amphetamine by rats, Psychopharmacologia 12:158–163.PubMedGoogle Scholar
  230. Pickens, R., Thompson, T., and Yokel, R. A., 1972, Characteristics of amphetamine self-administration by rats, in Current Concepts of Amphetamine Abuse (E. H. Ellinwood, Jr., and S. Cohen, eds.), pp. 43–48, DHEW Publ. No. HSM 72-9085, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  231. Pinkerton, 1813, General Collection of Voyages and Travels, Vol. XIV, pp. 448, London.Google Scholar
  232. Piness, G., Miller, H., and Alles, G. A., 1930, Clinical observations on aminoethanol sulfate, J.A.M.A. 94:790–791.Google Scholar
  233. Pollack, B., 1964, Report on an unusually large dosage of methylphenidate hydrochloride, Am. J. Psychiat. 121:189–190.PubMedGoogle Scholar
  234. Post, R. M., 1975a, Cocaine psychosis a continuum model, Am. J. Psychiat. 132:225–231.PubMedGoogle Scholar
  235. Post, R. M., 1975b, Comparative psychopharmacology of cocaine and amphetamine, presented at ACNP Meeting, San Juan, Puerto Rico, December 19, 1975.Google Scholar
  236. Post, R. M., and Kopanda, R. T., 1976, Cocaine, kindling and psychosis, Am. J. Psychiat. 133:627–634.PubMedGoogle Scholar
  237. Post, R. M., Kopanda, R. T., and Lee, A., 1975, Progressive behavioral changes during chronic lidocaine administration: Relationship to kindling, Life Sci. 17:943–950.PubMedGoogle Scholar
  238. Post, R. M., Kopanda, R. T., and Black, K. E., (1976), Progressive effects of cocaine on behavior and central amine metabolism in Rhesus monkeys, Biol. Psychiat. 11:403–419.PubMedGoogle Scholar
  239. Prinzmetal, M., and Bloomberg, W., 1935, Use of benzedrine for the treatment of narcolepsy, J.A.M.A. 105:2051–2054.Google Scholar
  240. Prokop, K., 1968, Halluzinose bei ephedrinsucht (hallucinosis in ephedrine addiction), Nervenarzt 39:71–75.PubMedGoogle Scholar
  241. Quinn, P. O., and Rapoport, J. L., 1975, One year following of hyperactive boys treated with imipramine or methylphenidate, Am. J. Psychiat. 132:241–245.PubMedGoogle Scholar
  242. Radin, P., 1942, Indians of South America, pp. 205, Doubleday, Company, New York.Google Scholar
  243. Randrup, A., and Munkvad, I., 1967, Stereotyped activities produced by amphetamine in several animal species and man, Psychopharmacologia 11:300–310.PubMedGoogle Scholar
  244. Randrup, A., and Munkvad, I., 1970, Biochemical, anatomical and psychological investigation of stereotyped behavior induced by amphetamines, in Amphetamines and Related Compounds (E. Costa and S. Garattini, eds.), pp. 695–713, Raven Press, New York.Google Scholar
  245. Ray, O. S., 1972, Drugs, Society, and Human Behaviors, p. 160, C. B. Mosby Co., St. Louis, Missouri.Google Scholar
  246. Reifenstein, E. C., Jr., and Davidoff, E., 1939, Benzedrine sulfate therapy, the present status, N. Y. State J. Med. 1939:42–57.Google Scholar
  247. Revetz, E., 1959, Sixth Spring Symp. Overweight and Underweight, Michigan Academy of General Practice, p. 99, Detroit, Michigan.Google Scholar
  248. Rioux, B., 1960, Is Ritalin an addiction producing drug, Dis. Nerv. Syst. 21:346–349.PubMedGoogle Scholar
  249. Robinson, A. E., and Wolkind, S. N., 1970, Amphetamine abuse amongst psychiatric in-patients: The use of chromatography, Br. J. Psychiat. 116:643–644.Google Scholar
  250. Rockwell, D. A., and Ostwald, P., 1968, Amphetamine use and abuse in psychiatric patients, Arch. Gen. Psychiat. 18:612–616.PubMedGoogle Scholar
  251. Rubovits, R., and Klawans, H. L., 1972, Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias, Arch. Gen. Psychiat. 27:502–507.PubMedGoogle Scholar
  252. Rumbaugh, C. L., Bergeron, R. T., Fang, H. C. H., and McCormick, R., 1971, Cerebrovascular changes secondary to amphetamine abuse in the experimental animal, Neuroradiology 101:345–351.Google Scholar
  253. Rylander, G., 1969, Clinical and medica-criminological aspects of addiction to central stimulating drugs, in Abuse of Control Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 251–273, Almqvist and Wiksell, Stockholm.Google Scholar
  254. Rylander, G., 1971, Stereotype behaviour in man following amphetamine abuse, in The Correlation of Adverse Effects in Man with Observations in Animals (S. B. De C. Baker, ed.), pp. 28–31, Excerpta Medica, Amsterdam.Google Scholar
  255. Sadusk, J. R., 1966, Non-narcotic addiction size and extent of the problem, J.A.M.A. 196:707–709.Google Scholar
  256. Salsbury, C. A., and Wayland, R. B., 1966, The uses and misuses of amphetamines, Medicoleg. Bull. 156:1–9.Google Scholar
  257. Sano, I., and Nagasaka, 1956, Über chronische Weckaminsucht in Japan, Fortschr. Neurol. Psychiat. 24:391–394.PubMedGoogle Scholar
  258. Sathananthan, G., Angrist, B., and Gershon, S., 1973, Response threshold to L-Dopa in psychiatric patients, Biol. Psychiat. 7:139–145.PubMedGoogle Scholar
  259. Scheel-Kruger, J., 1971, Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of catecholamines in the brain, Eur. J. Pharmacol. 14:47–59.PubMedGoogle Scholar
  260. Scheel-Kruger, J., 1972, Behavioral and biochemical comparison of amphetamine derivatives, cocaine, benztropine, and tricyclic antidepressant drugs, Eur. J. Pharmacol. 18:63–73.PubMedGoogle Scholar
  261. Scher, J., 1966, Patterns and profiles of addiction and drug abuse, Arch. Gen. Psychiat. 15:539–551.PubMedGoogle Scholar
  262. Schildkraut, J. J., Watson, R., Draskoczy, P. R., and Hartman, E., 1971, Amphetamine withdrawal depression and MHPG excretion, Lancet 1:485–486.Google Scholar
  263. Schroff, C., 1862, Vorläufige Mittheilungen über Cocain, Wchnbl. Gesellsch. Aertze Wien, XVIII:233.Google Scholar
  264. Schuster, C. R., and Fishman, M. W., 1975, Amphetamine toxicity: behavioral and neuropathological indexes current status of behavioral pharmacology, Fed. Proc. 34:1845–1851.PubMedGoogle Scholar
  265. Schuster, C. R., Woods, J. H., and Seevers, M. H., 1969, Self-administration of control stimulants by the monkey, in Abuse of Control Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 339–347, Almqvist and Wiksell, Stockholm.Google Scholar
  266. Scott, P. D., and Wilcox, D. R. C., 1965, Delinquency and the amphetamines, Br. J. Psychiat. 111:865–875.Google Scholar
  267. Seaton, A., Duncan, J. P., Rose, K., and Scott, A. M., 1961, Diethylpropion in the treatment of refractory obesity, Br. Med. J. 1:1009–1011.PubMedGoogle Scholar
  268. Seiden, L., 1975, Contemporary issues in stimulant research, Presented at Duke University, November 10–12, 1975.Google Scholar
  269. Seltzer, V., and Tonge, S., 1976, Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J. Pharm. Pharmacol. Suppl. 27:16.Google Scholar
  270. Sharpley, A., 1964, Evening Standard, Feb. 3–6, and May 1, 1964.Google Scholar
  271. Siegler, P., 1962, Clinical use of methylphenidate, in The First Hahnemann Symposium on Psychosomatic Medicine (J. H. Nodine and J. H. Mover, eds.), pp. 582–587, Lea and Febiger, Philadelphia.Google Scholar
  272. Simpson, S. L., 1937, Correspondence—Benzedrine, Br. Med. J. 1:93.Google Scholar
  273. Slater, E., 1959, Book review of amphetamine psychosis by P. H. Connell, Br. Med. J. 1959:488.Google Scholar
  274. Smith, D. E., 1969, Analysis of variables in high dose methamphetamine dependence, J. Psychedel. Drugs 2:132–137.Google Scholar
  275. Smith, D. E., and Fischer, C. M., 1970, An analysis of 310 cases of acute high-dose methamphetamine toxicity in Haight-Ashbury, Clin. Toxicol. 3:117–124.PubMedGoogle Scholar
  276. Smith, G. M., and Beecher, H. K., 1959, Amphetamine sulfate and athletic performance, J.A.M.A. 170:542–557.Google Scholar
  277. Smith, R., 1969a, The world of the Haight-Ashbury speed freak, J. Psychedel. Drugs 2:172–188.Google Scholar
  278. Smith, R., 1969b, Traffic in amphetamines: Patterns of illegal manufacture and distribution, J. Psychedel. Drugs 2:30–41.Google Scholar
  279. Snyder, S. H., 1973, Amphetamine psychosis: A “model” schizophrenia mediated by catecholamines, Am. J. Psychiat. 130:61–67.PubMedGoogle Scholar
  280. Snyder, S. H., 1974, Madness and Brain, McGraw-Hill, New York.Google Scholar
  281. Spensley, J., and Rockwell, D. A., 1972, Psychosis during methylphenidate abuse, New Eng. J. Med. 286:880–881.PubMedGoogle Scholar
  282. Spiegelberg, Von U., 1954, Klinisch-psychiatrische Erfahrungen mit einem neuen antriebs steigernden Praparat: 2-Phenyl-3-methyl-tetrahydro-l,4-oxazin Hydrochlorid, Nervenarzt 25:276–283.PubMedGoogle Scholar
  283. Spitzbarth, H., Gersmeyer, E. F., and Bauer, H., 1953, Untersuchungen zur Kreislaufwirkung des 2-Phenyl-3-methyl-morpholins (A66) beim Menschen, Klin. Wochenschr. 31:806–808.PubMedGoogle Scholar
  284. Squibb, E. R., Squibb, E. H., and Squibb, C. F., 1885, An Ephemeris of Materia Medica, Pharmacy, Therapeutics, and Collateral Information, Vol. II, 1884 and 1885, pp. 600–601, Brooklyn, New York.Google Scholar
  285. Stevenson, W. B., 1825, Historical and Descriptive Narrative of Twenty Years’ Residence in South America, London.Google Scholar
  286. Stockman, R., 1912, The active principle of Catha edulis and historic account of stimulant narcotics, Pharm. J. 89:676–678, 685-687.Google Scholar
  287. Sudilovsky, A., 1975a, Effects of disulfiram on the amphetamine-induced behavioral syndrome in thecat as a model of psychosis, in Aminergic Hypotheses of Behavior: Reality or Cliche? (B. K. Bernard, ed.), pp. 109-135, NIDA Res. Monograph Series No. 3, Rockwell.Google Scholar
  288. Sudilovsky, A., 1975b, Disruption of behavior in cats by chronic amphetamine intoxication, Int. J. Neurology, 10:259–275.Google Scholar
  289. Sudilovsky, A., Nelson, L., and Ellinwood, E. H., Jr., 1974, Amphetamine dyskinesia: A direct observational study in cats, in Drug Addiction, Vol. 4, New Aspects of Analytical and Clinical Toxicology (J. M. Singh and A. Lal, eds.), pp. 17–43, Symposia Specialists, Miami.Google Scholar
  290. Tatetsu, S., 1964, Methamphetamine psychosis, Folia Psychiat. Neurol. Japron. Suppl. 7, 1964:377–380.Google Scholar
  291. Tatetsu, 1972, Methamphetamine psychosis in Current Concepts of Amphetamine Abuse (E. H. Ellinwood, Jr., and S. Cohen, eds.), pp. 159–161, DHEW Publ. No. HSM 72-9085, U.S. Govt. Printing Office, Washington, D.C.Google Scholar
  292. Taylor, N., 1966, Narcotics: Nature’s dangerous gifts, Dell, New York.Google Scholar
  293. Teigen, A., 1970, Development and therapy on dependence of amphetamines in Scandinavia, Pharmakopsychiat. Neuropsychopharm. 3:300–308.Google Scholar
  294. The Medical Letter on Drugs and Therapeutics, 1971, 13:101-102.Google Scholar
  295. Thomä, O., and Wick, H., 1954, Über einige tetrahydro-1,4-oxazine mit sympathicomimetischen Eigenschaften (on some tetrahydro-1,4-oxazines with sympathicomimetic properties) Naunyn Schmiedelberg, Arch. Pharm. Exp. Path. 222:540–554.Google Scholar
  296. Thompson, T., and Pickens, R., 1970, Stimulant self-administration by animals: some comparisons with opiate self-administration, Fed. Proc. 29:6–12.PubMedGoogle Scholar
  297. Time Magazine, 1937, May 10, p. 45.Google Scholar
  298. Towns, C. B., 1912, The peril of the drug Habit, Century Magazine 84:583.Google Scholar
  299. Unanue, H., 1794, Disertacion sobre el aspecto, cultivo, commercio y virtudes de la famosa planta del Peru nombrada Coca, Mercurio Peruano (Lima), XI:205–250.Google Scholar
  300. Utena, H., 1966, Behavioral aberrations in methamphetamine intoxicated animals and chemical correlates in the brain, Prog. Brain Res. 21B, Correlative Neurosciences, Part B, Clinical Studies, pp. 192–207, Elsevier, Amsterdam.Google Scholar
  301. von Anrep, B., 1880, Über die physiologische Wirkung des Cocain, Arch. Ges. Physiol. XXI.Google Scholar
  302. Vondracek, V., Prokupek, J., Fischer, R., and Ahrenbergova, M., 1968, Recent patterns of addiction in Czechoslovakia, Br. J. Psychiat. 114:285–292.Google Scholar
  303. von Tschudi, J. J., 1846, Reiseskizzen aus den Jahren 1832–1842, St. Gall.Google Scholar
  304. von Poeppig, E. 1836, Reise in Chile, Peru und auf dem Amazonen Strohme wahrend der Jahre 1827–1832, Leipzig.Google Scholar
  305. von Voightlander, P. H., Losey, E. G., and Triezenberg, H. J., 1975, Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment, J. Pharmacol. Exp. Therap. 193:88–94.Google Scholar
  306. Waizer, J., Hoffman, S. P., Polizos, P., and Engelhardt, D. M., 1974, Out-patient treatment of hyperactive school children with imipramine, Am. J. Psychiat. 131:587–591.PubMedGoogle Scholar
  307. Wallach, M. B., 1974, Drug induced stereotyped behavior: Similarities and differences, in Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes (E. Usdin, ed.), pp. 241–260, Raven Press, New York.Google Scholar
  308. Waud, S. P., 1938, The effects of toxic doses of benzyl methyl carbinamine (Benzedrine) in man, J.A.M.A. 110:206–207.Google Scholar
  309. Weddell, H. A., 1853, Notice sur la Coca, sa culture, sa preparation, son emploi et ses proprietes, Mem. Soc. Imp. et Center d’Agriculture, Paris.Google Scholar
  310. Weiss, B., 1969, Enhancement of performance by amphetamine-like drugs, in Abuse of Central Stimulants (F. Sjoqvist and M. Tottie, eds.), pp. 31–60, Almqvist and Wiksell, Stockholm.Google Scholar
  311. Weiss, S. R., Raskind, R., Morgenstern, N. L., Pytlyk, P. J., and Baiz, T. C., 1970. Intracerebral and subarachnoid hemorrhage following use of methamphetamine (“speed”), Int. Surg. 53:124–125.Google Scholar
  312. Wharton, R. N., Perel, J. M., Dayton, P. G., and Malitz, S., 1971, A potential clinical use for methylphenidate with tricyclic antidepressants, Am. J. Psychiat. 127:1619–1625.PubMedGoogle Scholar
  313. WHO Expert Committee on Addiction-Producing Drugs, 1964, Thirteenth report, WHO Tech. Rep. Assoc. 273:9–10.Google Scholar
  314. Willey, R. F., 1971, Abuse of methylphenidate (Ritalin), New Eng. J. Med. 285:464.PubMedGoogle Scholar
  315. Wolfes, O., 1930, Über das Vorkommen von d-nor-iso-Ephedrin in Catha edulis, Arch. Pharm. Ber. Deutsch. Pharm. Gesellsch. 268:81–83.Google Scholar
  316. Yoss, R. E., and Daly, D. D., 1960, Narcolepsy, Med. Clin. N. Am. 44:953–958.PubMedGoogle Scholar
  317. Youngs, D., and Scoville, W. B., 1938, Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment, Med. Clin. N. Am. 22:637–646.Google Scholar
  318. Zalis, E. G., and Parmley, L. F., 1963, Fatal amphetamine poisoning, Arch. Int. Med. 112:822–826.Google Scholar
  319. Zondek, L., 1958, Amphetamine abuse and its relation to other drug addictions, Psychiat. Neurol. (Basel) 135:227–246.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Burton Angrist
    • 1
  • Abraham Sudilovsky
    • 1
  1. 1.Neuropsychopharmacology Research Unit, Department of PsychiatryNew York University Medical CenterNew YorkUSA

Personalised recommendations